fda-and-biotech News
Vistagen Eyes Year-End Data for Key Social Anxiety Drug Trial
Company completes enrollment for its pivotal PALISADE-3 study for fasedienol nasal spray, a crucial catalyst following a mixed quarterly report.
Phio Pharma Surges on Promising Skin Cancer Trial Data, New Funding
Biotech company reports compelling tumor clearance rates in its lead drug candidate and extends its cash runway into the first half of 2027.
Alumis Shares Fall After Q3 Revenue Misses Estimates by 34%
The clinical-stage biopharma posted a $110.8M net loss driven by R&D, shifting investor focus to its cash runway and pivotal 2026 data readouts.
BioAtla Slides as Cash Concerns Overshadow Clinical Progress
Shares fall over 4% after the biotech firm's wider net loss and low cash reserves eclipse positive trial updates and plans for a strategic deal.
Kodiak Sciences Slides as Financing Concerns Eclipse Clinical Progress
Shares fall over 6% after the company flags 'substantial doubt' about its ability to continue, overshadowing positive trial data and a recent analyst upgrade.
Eledon Pharma Shares Fall After Pricing $50M Stock Offering
The capital raise follows a steep drop in the company's stock last week after its lead drug candidate produced mixed results in a Phase 2 clinical trial.
Biotech Sector Rallies as FDA Taps 'Approval Accelerator' to Top Drug Post
Dr. Richard Pazdur, credited with revolutionizing cancer drug reviews, is set to lead the FDA's main drug center following an ethics scandal.
Centessa Pharma Dips After Pricing $250M Share Offering
The clinical-stage biotech priced the offering at $21.50 per share, a discount to its last close, representing over 8% dilution for existing shareholders.